Loading...
•
Sep 30, 2025
MannKind Q3 2025 Earnings Report
MannKind reported solid Q3 2025 results with increased revenues across key product lines and a notable rise in non-GAAP profitability.
Key Takeaways
MannKind posted Q3 2025 revenues of $82.1 million, a 17% increase from the prior year, driven by growth in royalties, Afrezza sales, and collaborations. GAAP net income declined slightly, while non-GAAP net income rose significantly.
Total Q3 2025 revenue rose to $82.1 million, up from $70.1 million in Q3 2024
Net income was $8.0 million, down from $11.6 million a year ago
Non-GAAP net income increased to $22.4 million from $15.4 million
Afrezza revenue grew 23% year-over-year to $18.5 million
Revenue by Segment
Forward Guidance
MannKind anticipates sustained revenue growth from its expanded portfolio following the scPharmaceuticals acquisition, with multiple regulatory and clinical milestones expected in 2026.
Positive Outlook
- FUROSCIX ReadyFlow Autoinjector sNDA submitted to FDA
- Afrezza pediatric sBLA accepted for FDA review; PDUFA May 2026
- MNKD-101 Phase 3 trial reached interim enrollment target ahead of schedule
- MNKD-201 Phase 2 trial initiated with enrollment expected Q1 2026
- scPharmaceuticals acquisition expected to drive future product revenue
Challenges Ahead
- Q3 net income declined YoY despite revenue growth
- V-Go product revenue decreased 19% due to lower demand
- Impairment loss of $6.4 million recorded on Thirona investment
- Higher SG&A expenses due to acquisition-related costs and Afrezza promotion
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...